Removing the barriers to higher education
Donor generosity is opening doors for students who might never have imagined university as an option. Through Griffith’s EmpowerED program, students are equipped with the skills, support, and financial assistance they need to succeed.
This support means I can finish my degree faster and create a better future for my son.
Megan Reid
Thanks to a partnership with the Bourne Foundation, students like Megan Reid have been able to embrace their education with confidence.
As a 22-year-old single mum, Megan dreamed of building a better future but was faced with the overwhelming challenge of balancing study and family.
With donor support, a bursary through EmpowerED gave her the tools to succeed—a dedicated study space, a laptop and the security of daycare for her child, making full-time study possible.
Now Megan is paying it forward, mentoring the next cohort of students and proving that, with the right support, transformative education is for all. “This support means I can finish my degree faster and create a better future for my son. I’m so grateful for the financial boost that helped me get here.”
More than $100 million of philanthropy has already been secured to create a brighter future for all.
Read more impact stories
Scholarship supports Indigenous women in law
Alicia George, whose passion for human rights and the rights of minorities, is the first recipient of a new scholarship that will nurture the next generation of female Aboriginal and Torres Strait Islander legal professionals.
Brighter Future scholarship recipient
Jake Philpott’s interest in physiotherapy is very personal. When he was just three, his father sustained a back injury that led to a lifetime of chronic pain and physical disability. To make matters worse, the family didn’t have access to adequate healthcare.
Trialling a groundbreaking Strep A vaccine
A life-saving vaccine is one step closer with scientists at Griffith leading an international partnership to create a Strep A vaccine that effective against the bacteria’s many strains and its resistance to immunity, with human clinical trials underway.